Clinical Trial Update: Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update showing enrollment for a head-to-head comparison of apixaban versus rivaroxaban in non-valvular atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Les Laboratoires des Médicaments Stériles | Conditions: Non Valvular Atrial Fibrillation | Phase 4 | Status: ENROLLING_BY_INVITATION